245 results about "Lymphatic vessel" patented technology

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

The present invention relates to formulations, methods and devices for delivering one or more biologically active agents, particularly a diagnostic or therapeutic agent to the intradermal compartment of a subject's skin. The present invention provides an improved method of delivery of biologically active agents in that it provides among other benefits, rapid uptake into the local lymphatics, improved targeting to a particular tissue, improved bioavailability, improved tissue bioavailability, improved tissue specific kinetics, improved deposition of a pre-selected volume of the agent to be administered. This invention provides methods for rapid transport of agents through lymphatic vasculature accessed by intradermal delivery of the agent. Methods of the invention are particularly useful for delivery of diagnostic and therapeutic agents. The invention relates to the synergy gained in diagnosing and treating disease when intradermal delivery and controlled release materials are combined. Specifically, the synergy is achieved when intradermal delivery is combined with lipid based particles.

The present invention provides methods to culture and use vascular endothelial cells, including lymphatic, venous and arterial endothelial cells.

An exemplary embodiment providing one or more improvements includes cushions which support a patient's thighs and lower legs and which have cut out areas in the areas of the patient's popliteal fossa at the back of the patient's knees. By avoiding contact with the popliteal fossa complications such as compression of the patient's nerves and blood vessels are avoided. This prevents the harmful effects of pressure on the popliteal fossa in loss of sensation in the lower legs and feet, and occlusion of blood and lymph vessels in the lower legs. A number of embodiment cushions are disclosed, some embodiments comprised of a relatively firm core foam material with a relatively softer viscoelastic foam in areas which are in contact with the patient's skin.

The invention relates to a method and an apparatus for the endothelium-preserving treatment of isolated hollow organs, especially biological vessels such as blood vessels and lymphatic vessels by means of endothelium-protective perfusates or incubation solutions containing at least 0.1 percent by weight of native albumin and a nutrient substrate, preferably L-glutamine. Also disclosed are the use of the endothelium-protective perfusates for preparing hollow organs or biological vessels as a transplant for the treatment of organ diseases or vascular diseases, the use thereof for repairing endothelial lesions in isolated hollow organs and/or biological vessels, and the use thereof for preserving organs and/or vessels.

The invention relates to a polysaccharide macromolecular paramagnetic metal complex and a synthesis method and an application thereof. Polysaccharide macromolecules are used as carriers, and a ligand compound, the side chains of which contain open-chain or annular polyamino polycarboxylic compounds, acts with paramagnetic metal ions to form the paramagnetic metal complex, wherein the paramagnetic metal ions are positive divalent or trivalent ions of metal elements, the atomic numbers of which are 21-29, 42 and 44 or 57-71. The polysaccharide macromolecular paramagnetic metal complex can be used as a magnetic resonance imaging contrast agent for lymphatic organs, lymphatic vessels, lymphatic systems and cardiovascular systems of people or other mammals.

Aspects of the present invention are drawn to methods and compositions for producing endothelial progenitor cells (EPCs) in vitro from pluripotent stem cells and compositions containing such EPCs. The methods produce sufficient EPCs to use in therapeutic applications. In certain embodiments the EPCs are bipotent, giving rise to both vascular and lymphatic endothelial cells. In certain embodiments, EPCs express one or more of the following gene products: LYVE-1, PV-1/PAL-E, CD31, and CD34.

A main object of the present invention is to provide a cell transfer substrate capable of transplanting cells, maintaining a pattern as it is, on a living body tissue or the like, even when: the size of the cell sheet is extremely small; the cells are cultured sparsely; the cells are in a form of a small colony; or the cells are cultured in a pattern, for example, as a blood vessel, a vessel network such as a lymphatic vessel, or a nerve network, and to provide a substrate for cell transfer to be used for the cell transfer substrate. In order to achieve the above-mentioned object, the present invention provides a substrate for cell transfer comprising: a polymer base material; an intermediate layer formed on the polymer base material; and a cell transfer layer formed on the intermediate layer.

A method of treating the heart and other body tissues by injecting a compound comprised of microsphere encapsulated macromolecule therapeutic agents into the myocardium, such that the microsphere size inhibits capillary transport of the compound but may permit lymphatic transport of the compound, and the compound releases therapeutic agents upon degradation of the microsphere. The compounds may be used in a method of treating the coronary arteries in which lymphatic transportable therapeutic agents are injected into the myocardium at a location distal to a target site in the coronary artery, after which they are taken up by the lymphatic vessels and transported proximally relative to the coronary artery, and migrate from the lymphatic vessel to the coronary blood vessel.

The invention discloses an eye drop and a preparation method thereof, relating to an eye drop. The invention provides an eye drop with short action time, high purity and relatively good effect and capability of simultaneously playing a role of corneal neovascularization, lymphangiogenesis and cornea inflammation resistance and a preparation method thereof. The eye drop contains the following components by volume percent: 0.1-5% of bovine serum, 5-15% of thickening agent, 1-5% of acid-base regulating solution, 0.5-2% of antibiotics, 5-20% of recombinant protein and the balance of balanced salt solution. The eye drop contains the balanced salt solution, the thickening agent, the bovine serum, the antibiotics, the acid-base regulating solution and the recombinant protein. The preparation method of the eye drop comprises the following steps of: adding the thickening agent, the bovine serum, the antibiotics and the recombinant protein to the balanced salt solution, regulating a pH value by using the acid-base regulating solution and osmotic pressure by using an osmotic pressure buffering agent, and removing bacteria through membrane filtration; or preparing the bovine serum to sterile micropowder, dissolving the bovine serum into the balanced salt solution, regulating the pH value, removing the bacteria through the membrane filtration, and dissolving recombined powder into the solution so as to obtain the eye drop.

The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.